Ficlatuzumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Ficlatuzumab is a monoclonal antibody designed for the treatment of various types of cancer. It specifically targets the hepatocyte growth factor (HGF), which plays a key role in the process of tumorigenesis, particularly in the proliferation, survival, and migration of cancer cells. Ficlatuzumab works by inhibiting the activity of HGF and thereby disrupting the signaling pathways that promote cancer cell growth and survival.
Mechanism of Action[edit | edit source]
Ficlatuzumab binds to HGF, preventing it from interacting with its receptor, c-Met. The HGF/c-Met signaling pathway is critical in the development and progression of many cancers, including lung cancer, breast cancer, and gastric cancer. By inhibiting this pathway, ficlatuzumab can reduce tumor growth and potentially improve patient outcomes.
Clinical Trials[edit | edit source]
Ficlatuzumab has been evaluated in various clinical trials, primarily focusing on its efficacy and safety in patients with non-small cell lung cancer (NSCLC). These studies have explored its use as both a monotherapy and in combination with other therapeutic agents, such as chemotherapy and targeted therapy.
Development and Regulatory Status[edit | edit source]
As of the last update, ficlatuzumab is still in the clinical trial phase and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. Ongoing research and clinical trials continue to assess its potential as a therapeutic option in oncology.
Potential Side Effects[edit | edit source]
Like all therapeutic antibodies, ficlatuzumab may cause side effects, which can vary from mild to severe. Common side effects observed in clinical trials include fatigue, nausea, and infusion-related reactions. More severe side effects may include liver toxicity and pulmonary complications.
Future Prospects[edit | edit source]
Research continues to explore the full potential of ficlatuzumab in treating various cancers. Its effectiveness in combination with other treatments and potential benefits over existing therapies are areas of active investigation.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
